Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
210 questions in 21 reviews · Lung Cancer
current versionsNo studies 15 · 7.1%Ungraded 2 · 1%Very low 15 · 7.1%Low 66 · 31.4%Moderate 50 · 23.8%High 62 · 29.5%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Gefitinib vs chemotherapy Asthenia · advanced NSCLC Gefitinib for advanced non‐small cell lung cancer (2018) · Cochrane | RR 0.51 [0.35, 0.75] | 3 studies · 1773 participants | High |
Gefitinib vs chemotherapy Neurotoxicity · advanced NSCLC Gefitinib for advanced non‐small cell lung cancer (2018) · Cochrane | RR 0.07 [0.01, 0.34] | 2 studies · 1529 participants | High |
Intervention NR Median overall survival · people with malignant pleural mesothelioma Radical multimodality therapy for malignant pleural mesothelioma (2018) · Cochrane | no estimate extracted | 1 study · 54 participants | Moderate |
Intervention NR Treatment‐related death · people with malignant pleural mesothelioma Radical multimodality therapy for malignant pleural mesothelioma (2018) · Cochrane | no estimate extracted | 1 study · 50 participants | Low |
Intervention NR Health‐related health‐related quality of life · people with malignant pleural mesothelioma Radical multimodality therapy for malignant pleural mesothelioma (2018) · Cochrane | no estimate extracted | 1 study · 54 participants | Low |
Intervention NR Adverse events · people with malignant pleural mesothelioma Radical multimodality therapy for malignant pleural mesothelioma (2018) · Cochrane | no estimate extracted | 1 study · 54 participants | Low |
Intervention NR Postoperative complications · people with malignant pleural mesothelioma Radical multimodality therapy for malignant pleural mesothelioma (2018) · Cochrane | no estimate extracted | 1 study · 54 participants | Low |
Intervention NR Treatment‐related death · people with malignant pleural mesothelioma Radical multimodality therapy for malignant pleural mesothelioma (2018) · Cochrane | no estimate extracted | 1 study · 54 participants | Low |
Intervention NR Median overall survival · people with malignant pleural mesothelioma Radical multimodality therapy for malignant pleural mesothelioma (2018) · Cochrane | no estimate extracted | 1 study · 50 participants | Moderate |
Intervention NR Health‐related health‐related quality of life · people with malignant pleural mesothelioma Radical multimodality therapy for malignant pleural mesothelioma (2018) · Cochrane | no estimate extracted | 1 study · 50 participants | Low |
Intervention NR Adverse events · people with malignant pleural mesothelioma Radical multimodality therapy for malignant pleural mesothelioma (2018) · Cochrane | no estimate extracted | 1 study · 50 participants | Low |
Intervention NR Progression‐free survival · people with malignant pleural mesothelioma Radical multimodality therapy for malignant pleural mesothelioma (2018) · Cochrane | no estimate extracted | 1 study · 50 participants | Low |
Intervention NR Survival · People with limited‐stage small‐cell lung cancer Surgery for limited‐stage small‐cell lung cancer (2017) · Cochrane | no estimate extracted | 3 studies · 330 participants | Very low |
Intervention NR Treatment related mortality · People with limited‐stage small‐cell lung cancer Surgery for limited‐stage small‐cell lung cancer (2017) · Cochrane | no estimate extracted | 2 studies · 290 participants | Very low |
Intervention NR Loco‐regional progression · People with limited‐stage small‐cell lung cancer Surgery for limited‐stage small‐cell lung cancer (2017) · Cochrane | no estimate extracted | 2 studies · 186 participants | Very low |
Intervention NR Quality of life · People with limited‐stage small‐cell lung cancer Surgery for limited‐stage small‐cell lung cancer (2017) · Cochrane | no estimate extracted | 1 study · 144 participants | Very low |
Intervention NR year overall survival in patients of good performance status (WHO performance status 0‐1) · adults with non small cell lung cancer who are not felt to be curable Palliative radiotherapy regimens for patients with thoracic symptoms from non‐small cell lung cancer (2015) · Cochrane | no estimate extracted | 8 studies · 1081 participants | Low |
Intervention NR year overall survival in patients of poor performance status (WHO performance status 2‐4) · adults with non small cell lung cancer who are not felt to be curable Palliative radiotherapy regimens for patients with thoracic symptoms from non‐small cell lung cancer (2015) · Cochrane | RR 0.96 [0.91, 1.02] | 7 studies · 911 participants | Moderate |
Intervention NR Oesophagitis (grade 3 to 4) · adults with non small cell lung cancer who are not felt to be curable Palliative radiotherapy regimens for patients with thoracic symptoms from non‐small cell lung cancer (2015) · Cochrane | RR 1.23 [0.81, 1.87] | 8 studies · 1301 participants | Low |
Intervention NR Radiation Myelopathy (any grade) · adults with non small cell lung cancer who are not felt to be curable Palliative radiotherapy regimens for patients with thoracic symptoms from non‐small cell lung cancer (2015) · Cochrane | RR 1.29 [0.37, 4.51] | 11 studies · 2663 participants | Moderate |
Intervention NR Radiation pneumonitis (any grade) · adults with non small cell lung cancer who are not felt to be curable Palliative radiotherapy regimens for patients with thoracic symptoms from non‐small cell lung cancer (2015) · Cochrane | RR 0.62 [0.23, 1.66] | 3 studies · 533 participants | Low |
Non‐platinum single‐agent vs non‐platinum combination treatment Overall survival (OS) · non‐small cell lung cancer in the elderly population Chemotherapy for advanced non‐small cell lung cancer in the elderly population (2015) · Cochrane | HR 0.92 | 5 studies · 1294 participants | Low |
Non‐platinum therapies vs platinum combination 1‐Year survival rate · non‐small cell lung cancer in the elderly population Chemotherapy for advanced non‐small cell lung cancer in the elderly population (2015) · Cochrane | RR 0.89 | 13 studies · 813 participants | Moderate |
Non‐platinum therapies vs platinum combination Progression‐free survival · non‐small cell lung cancer in the elderly population Chemotherapy for advanced non‐small cell lung cancer in the elderly population (2015) · Cochrane | HR 0.76 | 9 studies · 9 participants | Low |
Non‐platinum therapies vs platinum combination Objective response rate (ORR) · non‐small cell lung cancer in the elderly population Chemotherapy for advanced non‐small cell lung cancer in the elderly population (2015) · Cochrane | RR 1.57 | 11 studies · 1432 participants | Moderate |
Non‐platinum therapies vs platinum combination Grade 3 or higher hematological toxicity for platinum therapies ‐ anemia · non‐small cell lung cancer in the elderly population Chemotherapy for advanced non‐small cell lung cancer in the elderly population (2015) · Cochrane | RR 2.53 | 11 studies · 1437 participants | Low |
Non‐platinum therapies vs platinum combination Grade 3 or higher hematological toxicity for platinum therapies ‐ thrombocytopenia · non‐small cell lung cancer in the elderly population Chemotherapy for advanced non‐small cell lung cancer in the elderly population (2015) · Cochrane | RR 3.59 | 9 studies · 1260 participants | Low |
Non‐platinum therapies vs platinum combination Grade 3 or higher Non‐Hematological Toxicity for Platinum‐based therapies ‐ Peripheral neuropathy · non‐small cell lung cancer in the elderly population Chemotherapy for advanced non‐small cell lung cancer in the elderly population (2015) · Cochrane | RR 7.02 | 5 studies · 776 participants | Low |
Non‐platinum therapies vs platinum combination Quality of life (QoL) · non‐small cell lung cancer in the elderly population Chemotherapy for advanced non‐small cell lung cancer in the elderly population (2015) · Cochrane | no estimate extracted | 5 studies · 5 participants | Ungraded |
Non‐platinum single‐agent vs non‐platinum combination treatment 1‐Year survival rate (OS1y) · non‐small cell lung cancer in the elderly population Chemotherapy for advanced non‐small cell lung cancer in the elderly population (2015) · Cochrane | RR 0.88 | 4 studies · 993 participants | Low |
Non‐platinum single‐agent vs non‐platinum combination treatment Progression‐free survival · non‐small cell lung cancer in the elderly population Chemotherapy for advanced non‐small cell lung cancer in the elderly population (2015) · Cochrane | HR 0.94 | 4 studies · 1105 participants | Low |
Non‐platinum single‐agent vs non‐platinum combination treatment Objective response rate (ORR) · non‐small cell lung cancer in the elderly population Chemotherapy for advanced non‐small cell lung cancer in the elderly population (2015) · Cochrane | RR 1.79 | 5 studies · 1014 participants | Low |
Non‐platinum single‐agent vs non‐platinum combination treatment Grade 3 and 4 hematological adverse events (AE) ‐ anemia · non‐small cell lung cancer in the elderly population Chemotherapy for advanced non‐small cell lung cancer in the elderly population (2015) · Cochrane | RR 1.18 | 4 studies · 983 participants | Very low |
Non‐platinum single‐agent vs non‐platinum combination treatment Grade 3 and 4 hematological adverse events (AE) ‐ neutropenia · non‐small cell lung cancer in the elderly population Chemotherapy for advanced non‐small cell lung cancer in the elderly population (2015) · Cochrane | RR 1.19 | 5 studies · 1064 participants | Low |
Non‐platinum single‐agent vs non‐platinum combination treatment Grade 3 and 4 hematological adverse events (AE) ‐ thrombocytopenia · non‐small cell lung cancer in the elderly population Chemotherapy for advanced non‐small cell lung cancer in the elderly population (2015) · Cochrane | RR 1.58 | 4 studies · 995 participants | Very low |
Non‐platinum single‐agent vs non‐platinum combination treatment Quality of life (QoL) · non‐small cell lung cancer in the elderly population Chemotherapy for advanced non‐small cell lung cancer in the elderly population (2015) · Cochrane | no estimate extracted | 2 studies · 2 participants | Ungraded |
Non‐platinum therapies vs platinum combination Overall survival · non‐small cell lung cancer in the elderly population Chemotherapy for advanced non‐small cell lung cancer in the elderly population (2015) · Cochrane | HR 0.76 | 13 studies · 13 participants | Moderate |
Intervention NR Overall survival1 · Patients with advanced non‐small cell lung cancer Chemotherapy with cetuximab versus chemotherapy alone for chemotherapy‐naive advanced non‐small cell lung… (2014) · Cochrane | HR 0.87 [0.79, 0.96] | 4 studies · 2018 participants | High |
Intervention NR Progression‐free survival1 · Patients with advanced non‐small cell lung cancer Chemotherapy with cetuximab versus chemotherapy alone for chemotherapy‐naive advanced non‐small cell lung… (2014) · Cochrane | HR 0.91 [0.83, 1] | 4 studies · 2018 participants | Low |
Intervention NR One‐year survival rate2 · Patients with advanced non‐small cell lung cancer Chemotherapy with cetuximab versus chemotherapy alone for chemotherapy‐naive advanced non‐small cell lung… (2014) · Cochrane | RR 1.13 [1.02, 1.25] | 4 studies · 2018 participants | High |
Intervention NR Objective response rate2 · Patients with advanced non‐small cell lung cancer Chemotherapy with cetuximab versus chemotherapy alone for chemotherapy‐naive advanced non‐small cell lung… (2014) · Cochrane | RR 1.31 [1.14, 1.51] | 4 studies · 2018 participants | Low |
Intervention NR Quality of life3 · Patients with advanced non‐small cell lung cancer Chemotherapy with cetuximab versus chemotherapy alone for chemotherapy‐naive advanced non‐small cell lung… (2014) · Cochrane | no estimate extracted | 2 studies · 1801 participants | Low |
Intervention NR Serious adverse events2,4 · Patients with advanced non‐small cell lung cancer Chemotherapy with cetuximab versus chemotherapy alone for chemotherapy‐naive advanced non‐small cell lung… (2014) · Cochrane | RR 37.36 [10.66, 130.95] | 1 study · 4 participants | Low |
First‐line chemotherapy vs BSC Overall survival · patients with extensive SCLC without previous treatment Chemotherapy versus best supportive care for extensive small cell lung cancer (2013) · Cochrane | no estimate extracted | 2 studies · 65 participants | Very low |
First‐line chemotherapy vs BSC Adverse effects · patients with extensive SCLC without previous treatment Chemotherapy versus best supportive care for extensive small cell lung cancer (2013) · Cochrane | no estimate extracted | 2 studies · 65 participants | Very low |
Intervention NR Overall survival · patients with extensive SCLC who relapsed or progressed after first‐line chemotherapy Chemotherapy versus best supportive care for extensive small cell lung cancer (2013) · Cochrane | HR 0.73 [0.55, 0.96] | 2 studies · 542 participants | Low |
Intervention NR Toxic death · patients with extensive SCLC who relapsed or progressed after first‐line chemotherapy Chemotherapy versus best supportive care for extensive small cell lung cancer (2013) · Cochrane | no estimate extracted | 2 studies · 542 participants | Moderate |
Intervention NR Adverse effects · patients with extensive SCLC who relapsed or progressed after first‐line chemotherapy Chemotherapy versus best supportive care for extensive small cell lung cancer (2013) · Cochrane | no estimate extracted | 2 studies · 542 participants | Moderate |
Intervention NR Quality of life · patients with extensive SCLC who relapsed or progressed after first‐line chemotherapy Chemotherapy versus best supportive care for extensive small cell lung cancer (2013) · Cochrane | RR 2.18 [0.05, 0.25] | 1 study · 141 participants | Low |
Lung cancer screening with chest radiography +/‐ sputum cytology vs less intense screening Lung cancer mortality ‐ More frequent chest x‐ray screening versus less frequent screening · Patients with lung cancer Screening for lung cancer (2013) · Cochrane | RR 1.11 [0.95, 1.31] | 4 studies · 81303 participants | Moderate |